PARABILIS MEDICINES INC
PBLSNASDAQπ #1259 by market capEarnings Sep 2US Equity
$36.47β² $0.75 (+2.07%)
π
Pre-market$35.90βΌ 1.56%Regular close Β· extended-hours price shown1hβ
24hβ² 2.1%
7dβ² 4.6%
14dβ² 14.8%
30dβ² 23.5%
1yβ
π¦Market Cap
$4.25B
Small Cap
πRevenue Growth (YoY)
β
πGross Margin
β
π΅FCF Margin
β
βοΈP/S Ratio
β
Otter Score
66
Fair
Trading Snapshot
- Day Range
- $36.22 β $36.88
- 52-Week Range
- $24.51 β $36.95
- Volume
- $2.53B
- Avg Volume
- $2.21B
- Shares Outstanding
- 116.6M
- Next Earnings
- Sep 23, 2026
Fundamentals Snapshot
- Annual Revenue
- $675M
- Last Q Revenue
- $159M
- P/E Ratio
- β
- P/S Ratio
- β
- EPS (TTM)
- β
- Dividend Yield
- β
Why Investors Own PBLS
- βHigh-growth profile β revenue up +17.6% YoY with expanding US Equity exposure.
- βHealthy economics β 62% gross margin and 8% free-cash-flow margin.
- βNew products and segments could unlock additional revenue streams.
β οΈ Key Risks
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
Revenue (TTM)
$675Mβ² +17.2% YoY
Gross Margin (TTM)
61.9%β² +0.7% YoY
Operating Income (TTM)
$69Mβ² +17.2% YoY
Free Cash Flow (TTM)
$55Mβ² +17.2% YoY
About PARABILIS MEDICINES INC
Fog Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. It discovers and develops cell-penetrating miniproteins (CPMPs), which are specifically designed to target cancer-causing proteins inside cancer cells and neutralize them. The company was founded by Gregory L. Verdine, WeiQing Zhou and David Philip Lane in 2015 and is headquartered in Cambridge, MA.
π¦¦
Otter Score Breakdown
βπQualityβ
β
β
β
β
πGrowthβ
β
β
β
β
βοΈValuationβ
β
β
β
β
β‘Momentumβ
β
β
β
β
Overall Score
Fair
66/100
Analyst Ratings
βConsensus
Buy
10 analysts
Strong Buy5
Buy4
Hold1
Sell0
Strong Sell0
Ratings as of Aug 2026
